A detailed history of Stansberry Asset Management, LLC transactions in Harrow Health, Inc. stock. As of the latest transaction made, Stansberry Asset Management, LLC holds 96,450 shares of HROW stock, worth $4.35 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
96,450
Previous 115,144 16.24%
Holding current value
$4.35 Million
Previous $1.52 Million 32.24%
% of portfolio
0.29%
Previous 0.23%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$10.0 - $21.64 $186,940 - $404,538
-18,694 Reduced 16.24%
96,450 $2.01 Million
Q1 2024

May 14, 2024

SELL
$9.3 - $13.23 $225,794 - $321,211
-24,279 Reduced 17.41%
115,144 $1.52 Million
Q3 2023

Nov 14, 2023

BUY
$14.03 - $22.08 $172,470 - $271,429
12,293 Added 9.67%
139,423 $2 Million
Q2 2023

Aug 17, 2023

BUY
$17.37 - $28.08 $265,500 - $429,202
15,285 Added 13.67%
127,130 $2.42 Million
Q2 2023

Aug 11, 2023

SELL
$17.37 - $28.08 $242,815 - $392,530
-13,979 Reduced 11.11%
111,845 $2.13 Million
Q1 2023

May 12, 2023

SELL
$13.84 - $21.46 $4,899 - $7,596
-354 Reduced 0.28%
125,824 $2.66 Million
Q4 2022

Feb 13, 2023

BUY
$10.28 - $14.78 $1.3 Million - $1.86 Million
126,178 New
126,178 $1.86 Million
Q2 2022

Aug 15, 2022

SELL
$5.75 - $7.74 $15,617 - $21,021
-2,716 Reduced 1.89%
141,040 $1.03 Million
Q1 2022

May 16, 2022

BUY
$6.77 - $8.66 $67,815 - $86,747
10,017 Added 7.49%
143,756 $981,000
Q4 2021

Feb 14, 2022

BUY
$8.5 - $12.0 $672,358 - $949,212
79,101 Added 144.77%
133,739 $1.16 Million
Q3 2021

Nov 15, 2021

BUY
$6.99 - $10.6 $381,919 - $579,162
54,638 New
54,638 $497,000

Others Institutions Holding HROW

About HARROW HEALTH, INC.


  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $1.22B
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Stansberry Asset Management, LLC Portfolio

Follow Stansberry Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stansberry Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stansberry Asset Management, LLC with notifications on news.